Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of mosunetuzumab + lenalidomide versus rituximab + lenalidomide in relapsed or persistent follicular lymphoma
CTR20212185Phase 3Active
- Sponsor
- Roche
- Start
- Jan 2022
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mosunetuzumab in follicular lymphoma (FL) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival by IRC. Started Jan 2022; status: active.
02
Drugs
mosunetuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on CTR20212185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212185.